Thomas Tedder

Thomas Fletcher Tedder, Ph.D., (born May 14, 1956) is an American immunologist. He is best known for his work in the fields of B lymphocyte biology and regulation. He is currently the Alter E. Geller Professor for Research in Immunology at Duke University.[1]

Career

Tedder received his Ph.D. in molecular cell biology from the University of Alabama in 1984 and completed his postdoctoral training as a research fellow in pathology at Harvard Medical School. He was a faculty member at Dana-Farber Cancer Institute and Harvard Medical School from 1985 to 1998 before joining Duke University in 1993 as its founding chairman of immunology.[2] Tedder studies the structure and function of B lymphocyte cell surface molecules that regulate B cell function, activation, and signal transduction. He currently has 401 total publications and 25 issued patents relating to B cells and their products, including CD19, CD20, CD22, CD83, and L-selectin.[3] He has founded four biotherapeutic companies, including Angelica Therapeutics, Cellective Therapeutics, Cellective BioTherapy[4] and most recently, Antigenomycs, Inc.

The drug Tedder developed at Cellective Therapeutics, inebilizumab,[5] has now been approved for NMSOD use in the United States[6] under the clinical name Uplizna.

References
  1. "Duke Immunology". immunology.duke.edu. Archived from the original on 2016-08-03. Retrieved 11 August 2018.
  2. "Archived copy". Archived from the original on 2015-09-12. Retrieved 2015-10-19.CS1 maint: archived copy as title (link)
  3. "Angelica Therapeutics: Best in Class Fusion Toxins". angelicatherapeutics.com. Retrieved 11 August 2018.
  4. "Article". www.bizjournals.com. 2015.
  5. "Accelerating Immunotherapy | Duke Department of Neurosurgery". neurosurgery.duke.edu. Retrieved 2020-07-08.
  6. "Uplizna launch is a 'testament' to NC's prowess in drug R&D | WRAL TechWire". 2020-07-01. Retrieved 2020-07-08.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.